Brief: Active Biotech Says Naptumomab, Docetaxel Results To Be Presented At ASCO 2024

Active Biotech AB publ

28/05/2024 07:06

May 28 (Reuters) - Active Biotech AB publ  ACTI.ST :
    * CLINICAL ACTIVITY AND SAFETY OF NAPTUMOMAB AND DOCETAXEL
TO BE
PRESENTED AT ASCO 2024

Source text for Eikon:  ID:nMFNBZML8 
Further company coverage:  ACTI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))